A new review highlights the future of anti-obesity medications that could outperform today's already blockbuster drugs like Ozempic.

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

The results from the SUMMIT trial of tirzepatide in obese ... In the 731-patient SUMMIT study, participants were randomly assigned to either tirzepatide at a dose of between 2.5mg and 15mg per ...

“The investigators in the trials of the participants assigned to liraglutide and tirzepatide did not provide additional information about the causes of deaths and their relation to the trial ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

Participants in the 36-week trial experienced a nearly 10% reduction in body fat ... molecules used as the basis for obesity ...